ONE batch of Novartis' Duro-K 600 mg potassium chloride tablets supplied in Australia has higher levels of lead than permitted under new regulatory guidelines, but the Therapeutic Goods Administration has advised that the lead content in the affected batch does not present a significant health risk, even for people taking the maximum dose (12 tablets per day).
As of 13 Mar 2018, there have been no reports of adverse events relating to exposure to lead associated with Duro-K.
Based on these considerations, the TGA has determined that no further action is required.
Novartis has sent a letter to health professionals providing additional information and advises that if there are further questions or concerns, they can contact the company on 1800 671 203.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Mar 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Mar 18
